Cargando…

The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma

BACKGROUND: This study evaluated the impact of adjuvant therapies on patient survival and disease recurrence patterns to identify an effective adjuvant therapy for resected lower thoracic oesophageal squamous cell carcinoma (LTESCC). METHODS: Clinical data of 127 patients with stage IIa-IVa LTESCC w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yichun, Zhu, Liyang, Xia, Wanli, Wu, Liming, Wang, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223077/
https://www.ncbi.nlm.nih.gov/pubmed/30404621
http://dx.doi.org/10.1186/s12957-018-1516-1
_version_ 1783369353977135104
author Wang, Yichun
Zhu, Liyang
Xia, Wanli
Wu, Liming
Wang, Fan
author_facet Wang, Yichun
Zhu, Liyang
Xia, Wanli
Wu, Liming
Wang, Fan
author_sort Wang, Yichun
collection PubMed
description BACKGROUND: This study evaluated the impact of adjuvant therapies on patient survival and disease recurrence patterns to identify an effective adjuvant therapy for resected lower thoracic oesophageal squamous cell carcinoma (LTESCC). METHODS: Clinical data of 127 patients with stage IIa-IVa LTESCC with a minimum 2-year follow-up after oesophagectomy were analysed. The survival and recurrence patterns were compared among patients who received adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemoradiotherapy, or surgery alone. RESULTS: Eighty-eight patients (69.3%) were identified as having disease recurrence. The regional lymph node recurrence rate was 57.5%, and the recurrence rates were high in the lower neck, upper mediastinum, and upper abdomen. Compared to surgery alone, adjuvant radiotherapy or chemoradiotherapy significantly decreased the recurrence rate (p < 0.05). Adjuvant chemoradiotherapy significantly improved overall survival, disease-free survival, and locoregional recurrence-free survival compared to surgery alone (p = 0.01, 0.01, and 0.00, respectively). Pathologically positive lymph nodes (PPLNs) in the lower mediastinum represented a potential risk factor for cervical recurrence (HR 2.97, 95%CI 1.19–7.39). Multivariable analysis showed that postoperative radiotherapy (HR 0.30, 95%CI 0.13–0.68) and PPLNs in the upper mediastinum (HR 3.72, 95%CI 1.30–10.67) were independent risk factors for upper mediastinal recurrence, while postoperative radiotherapy (HR 0.37, 95%CI 0.16–0.85) and PPLNs in the abdomen (HR 2.57, 95%CI 1.12–5.92) were independent risk factors for abdominal recurrence. CONCLUSION: Adjuvant chemoradiotherapy was the most effective adjuvant therapy for resected stage IIa-IVa LTESCC. The lower neck, upper mediastinum, and upper abdomen were high-risk regions for postoperative radiotherapy. The regions of PPLNs may be important factors for individual targets.
format Online
Article
Text
id pubmed-6223077
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62230772018-11-19 The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma Wang, Yichun Zhu, Liyang Xia, Wanli Wu, Liming Wang, Fan World J Surg Oncol Research BACKGROUND: This study evaluated the impact of adjuvant therapies on patient survival and disease recurrence patterns to identify an effective adjuvant therapy for resected lower thoracic oesophageal squamous cell carcinoma (LTESCC). METHODS: Clinical data of 127 patients with stage IIa-IVa LTESCC with a minimum 2-year follow-up after oesophagectomy were analysed. The survival and recurrence patterns were compared among patients who received adjuvant radiotherapy, adjuvant chemotherapy, adjuvant chemoradiotherapy, or surgery alone. RESULTS: Eighty-eight patients (69.3%) were identified as having disease recurrence. The regional lymph node recurrence rate was 57.5%, and the recurrence rates were high in the lower neck, upper mediastinum, and upper abdomen. Compared to surgery alone, adjuvant radiotherapy or chemoradiotherapy significantly decreased the recurrence rate (p < 0.05). Adjuvant chemoradiotherapy significantly improved overall survival, disease-free survival, and locoregional recurrence-free survival compared to surgery alone (p = 0.01, 0.01, and 0.00, respectively). Pathologically positive lymph nodes (PPLNs) in the lower mediastinum represented a potential risk factor for cervical recurrence (HR 2.97, 95%CI 1.19–7.39). Multivariable analysis showed that postoperative radiotherapy (HR 0.30, 95%CI 0.13–0.68) and PPLNs in the upper mediastinum (HR 3.72, 95%CI 1.30–10.67) were independent risk factors for upper mediastinal recurrence, while postoperative radiotherapy (HR 0.37, 95%CI 0.16–0.85) and PPLNs in the abdomen (HR 2.57, 95%CI 1.12–5.92) were independent risk factors for abdominal recurrence. CONCLUSION: Adjuvant chemoradiotherapy was the most effective adjuvant therapy for resected stage IIa-IVa LTESCC. The lower neck, upper mediastinum, and upper abdomen were high-risk regions for postoperative radiotherapy. The regions of PPLNs may be important factors for individual targets. BioMed Central 2018-11-07 /pmc/articles/PMC6223077/ /pubmed/30404621 http://dx.doi.org/10.1186/s12957-018-1516-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wang, Yichun
Zhu, Liyang
Xia, Wanli
Wu, Liming
Wang, Fan
The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
title The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
title_full The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
title_fullStr The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
title_full_unstemmed The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
title_short The impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage IIa–IVa lower thoracic oesophageal squamous cell carcinoma
title_sort impact of adjuvant therapies on patient survival and the recurrence patterns for resected stage iia–iva lower thoracic oesophageal squamous cell carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223077/
https://www.ncbi.nlm.nih.gov/pubmed/30404621
http://dx.doi.org/10.1186/s12957-018-1516-1
work_keys_str_mv AT wangyichun theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT zhuliyang theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT xiawanli theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT wuliming theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT wangfan theimpactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT wangyichun impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT zhuliyang impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT xiawanli impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT wuliming impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma
AT wangfan impactofadjuvanttherapiesonpatientsurvivalandtherecurrencepatternsforresectedstageiiaivalowerthoracicoesophagealsquamouscellcarcinoma